[ad_1]
Health
14 March 2024, 2:54 pm 1 minute
Reuters was first to report on the FDA approving Madrigal Pharmaceuticals’ drug Rezdiffra, an oral drug to treat a fatty liver disease known as non-alcoholic steatohepatitis (NASH). The approval was the first of its kind.
Market Impact
The company’s shares surged 24% in extended trading.
Article Tags
Topics of Interest: Health
Type: Reuters Best
Sectors: Pharmaceuticals & Healthcare
Regions: Americas
Countries: United States
Win Types: Speed
Story Types: Exclusive / Scoop
Media Types: Text
Customer Impact: Significant National Story
[ad_2]
Source link
